ConductScience.org, home

Paper41368474

Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?

Elmustafa F and 6 others. Curr Hepatol Rep, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes? Papers, record 41368474. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41368474

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?
PubMed
Journal
Curr Hepatol Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-09-19
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Elmustafa FFatima
2Tyagi MMahima
3Kaur HHarpreet
4Blaney HHannahttps://orcid.org/0000-0003-4919-9519
5Xie CChencheng
6Jalil SSajidhttps://orcid.org/0000-0003-2315-2384
7Singal AKAshwani K

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
U01 AA026980NIAAA NIH HHSUnited StatesU01AA026980PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References128

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136644237A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.JHEP Rep2023https://conductscience.org/library/papers/36644237PubMed
226707137Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia.Dig Dis Sci2016https://conductscience.org/library/papers/26707137PubMed
338534155Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes.Am J Gastroenterol2024https://conductscience.org/library/papers/38534155PubMed
423355498Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study.Am J Epidemiol2013https://conductscience.org/library/papers/23355498PubMed
538664876Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.Aliment Pharmacol Ther2024https://conductscience.org/library/papers/38664876PubMed
636626630The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023https://conductscience.org/library/papers/36626630PubMed
722435761Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.Liver Int2012https://conductscience.org/library/papers/22435761PubMed
838806481Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.Nat Commun2024https://conductscience.org/library/papers/38806481PubMed
938428619Impact of Longitudinal Alcohol Use Patterns on Long-Term Risk of Cirrhosis Among US Veterans With Steatotic Liver Disease.Gastroenterology2024https://conductscience.org/library/papers/38428619PubMed
1035750137Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.J Hepatol2022https://conductscience.org/library/papers/35750137PubMed
1135468325
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Lancet Diabetes Endocrinol2022https://conductscience.org/library/papers/35468325PubMed
1214984242Ethyl glucuronide--the direct ethanol metabolite on the threshold from science to routine use.Addiction2003https://conductscience.org/library/papers/14984242PubMed
1338820071MetALD: Does it require a different therapeutic option?Hepatology2024https://conductscience.org/library/papers/38820071PubMed
1435798021The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2022https://conductscience.org/library/papers/35798021PubMed
1533440159Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH.Cell Rep2021https://conductscience.org/library/papers/33440159PubMed
1638266957Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.Metabolism2024https://conductscience.org/library/papers/38266957PubMed
1735761115Alcoholic liver disease: a new insight into the pathogenesis of liver disease.Arch Pharm Res2022https://conductscience.org/library/papers/35761115PubMed
1840517819Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification.J Hepatol2025https://conductscience.org/library/papers/40517819PubMed
1938174913ACG Clinical Guideline: Alcohol-Associated Liver Disease.Am J Gastroenterol2024https://conductscience.org/library/papers/38174913PubMed
2040283027Non-Invasive Tests as a Replacement for Liver Biopsy in the Assessment of MASLD.Medicina (Kaunas)2025https://conductscience.org/library/papers/40283027PubMed

See all 128 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42872032Metabolic dysfunction-associated steatotic liver disease (MASLD) versus metabolic dysfunction and alcohol-associated steatotic liver disease (Met-ALD), do the differences matter in clinical practice?Hepatobiliary Surg Nutr2026https://conductscience.org/library/papers/42872032PubMed
42577825Pharmacologic management of metabolic and alcohol-associated liver disease.Metab Target Organ Damage2026https://conductscience.org/library/papers/42577825PubMed
42227036Precision pathophysiology in steatotic liver disease.Clin Mol Hepatol2026https://conductscience.org/library/papers/42227036PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41368474

GET https://conductscience.org/api/papers/v1/41368474/references?page=2